A203 EARLY PROACTIVE DRUG MONITORING STRATEGY OF INFLIXIMAB AS MONOTHERAPY FOR INFLAMMATORY BOWEL DISEASE IN PAEDIATRIC PATIENTS IS ASSOCIATED WITH GOOD SUSTAINED CLINICAL REMISSION

BACKGROUND: Monotherapy with Infliximab (IFX) can be as efficient as combotherapy with immunomodulators in the treatment and maintenance of remission for children with inflammatory bowel disease (IBD) if an early proactive therapeutic drug monitoring strategy is adequately performed. This strategy m...

Descripción completa

Detalles Bibliográficos
Autores principales: Girard, C, Ackhar, S, Sassine, S, Chapuy, L, Jantchou, P, Deslandres, C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Poster Presentations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9991299/
http://dx.doi.org/10.1093/jcag/gwac036.203

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9991299/
http://dx.doi.org/10.1093/jcag/gwac036.203

Ejemplares similares